-
EHA Global Insight丨Dr. Uwe Platzbecker: Breakthrough Advances in Acute Promyelocytic Leukemia Treatment — Key Findings of the APOLLO Study
Acute promyelocytic leukemia (APL) is a highly aggressive hematological disease, and its treatment has long been a challenge in the field. Chinese scholars have contributed significantly to global APL treatment with the introduction of the arsenic trioxide (ATO) regimen. Since the publication of the APL0406 study in NEJM in 2013, the combination of all-trans retinoic…
-
EHA International Perspective | B-Pd Regimen—Professor Meletios A. Dimopoulos Reveals New Options for Second-Line Treatment
With the rapid development in the field of hematology, new treatment strategies and breakthrough advancements continue to emerge, offering new hope for patients with hematological malignancies. At the 2024 EHA conference, “Oncology Frontier-Hematology Frontier” had the honor of interviewing Professor Meletios A. Dimopoulos from the School of Medicine, National and Kapodistrian University of Athens School…
-
Does Post-TIPS Hepatic Encephalopathy Increase Mortality in Cirrhotic Patients?
Recently, a study by Italian scholar Dr. Silvia Nardelli, published in the Journal of Hepatology, found that even if cirrhotic patients develop overt hepatic encephalopathy (OHE) after undergoing transjugular intrahepatic portosystemic shunt (TIPS) surgery, their mortality rate does not significantly increase. This conclusion challenges previous perceptions of the negative impact of OHE in non-TIPS contexts,…
-
Delving into the Details: Dr. Zhanhong Chen & Dr. Rui Ge on First-Line Treatment Options for HER2-Positive Breast Cancer
When it comes to the “P” in the THP regimen for HER2-positive breast cancer, do you prefer Pertuzumab or Pyrotinib? At the 2024 Breast Cancer Summer Forum · Northern Salon’s “Root Cause” session, Dr. Zhanhong Chen from Zhejiang Cancer Hospital and Dr. Rui Ge from Huadong Hospital Affiliated to Fudan University shared their perspectives. Professor…
-
Dr. Wenxing Qin: Advances in Research on Drug Resistance Mechanisms of ADCs in Breast Cancer
A century ago, Paul Ehrlich, the father of German immunology, proposed the concept of the “Magic Bullet,” which targets toxic drugs to microorganisms or tumor cells. With continuous technological breakthroughs, Antibody-Drug Conjugates (ADCs) have seen explosive approval. These drugs combine specific monoclonal antibodies with highly active cytotoxic drugs via linkers, balancing the specificity of targeted…
-
New Concepts in Regional Treatment of Breast Cancer and Future Outlook by Dr. Yongsheng Wang | 2024 CACA Integrated Breast Cancer Conference
At the 2024 China Anti-Cancer Association (CACA) Integrated Breast Cancer Conference, Dr. Yongsheng Wang from Shandong Cancer Hospital elaborated on new concepts in regional treatment for breast cancer. He emphasized that local regional treatment for breast cancer patients should comprehensively consider the risk of recurrence and metastasis, the efficacy and adverse effects of systemic treatment,…
-
Comprehensive Review of Chemotherapy-Induced Anemia Management in China （1）
Cancer-related anemia (CRA) encompasses anemia that occurs in cancer patients during disease progression or treatment, including non-chemotherapy-related CRA and chemotherapy-induced anemia (CIA). With the increase in chemotherapy treatments, the incidence of anemia is significant, with over 90% of patients not receiving any corrective treatment. To gain a comprehensive understanding of the current practices and perceptions…
-
CD7 CAR-T Combined with Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Improves Survival in r/r T-ALL/LBL Patients
Relapsed/refractory acute T-cell lymphoblastic leukemia/T-cell lymphoblastic lymphoma (r/r T-ALL/LBL) presents significant treatment challenges with poor prognosis. Data show that the 5-year survival rate is less than 25%, and even with salvage allo-HSCT, the 3-5 year survival rate is only 14-30%. Improving survival for these patients has become a hot research topic. Recently, Professor Xingyu Cao’s team…
Connecting Medical Expertise through Media